An investigation for investors who currently hold NASDAQ:VASC shares concerning potential wrongdoing at Vascular Solutions was announced and long-term NASDAQ:VASC stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/27/2015 -- An investigation for investors who currently hold NASDAQ:VASC shares is ongoing concerning whether certain Vascular Solutions officers and directors breached their fiduciary duties and caused damages to the company and its shareholders.
Investors who purchased shares of Vascular Solutions, Inc. (NASDAQ:VASC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vascular Solutions officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On November 13, 2014, a federal grand jury indicted Vascular Solutions' CEO, Howard Root, on charges he conspired to sell a varicose-vein treatment device for unapproved uses. The nine count indictment alleges Vascular Solutions, Inc improperly marketed its Vri-Lase device kit for use on veins deep in the leg, even though it was only approved for use on superficial blood vessels and a clinical trial showed adverse events when Vari-Lase was used on deeper veins. Shares of Vascular Solutions, Inc dropped from almost $31 per share on November 13, 2014, to as low as $23.23 per share on November 13, 2014.
Those who purchased shares of Vascular Solutions, Inc. (NASDAQ:VASC), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com